FINWIRES · TerminalLIVE
FINWIRES

Life's Profit Rises 4.9% in Fiscal 2025

By

Life Corporation's (TYO:8194) profit attributable to owners of the parent rose 4.9% to 18.8 billion yen in the fiscal year 2025 from 17.9 billion yen a year earlier.

The supermarket chain operator's basic earnings per share increased to 217.56 yen from 195.11 yen a year ago, according to a Tokyo bourse filing on Friday.

Operating revenue climbed 3.6% to 881.3 billion yen in the year ended Feb. 28 from 850.5 billion yen in the prior year.

Life declared a final dividend of 33 yen per share for the fiscal year 2025, payable from May 29.

For the fiscal year ending Feb. 28, the company expects attributable profit of 19 billion yen, EPS of 218.86 yen, and operating revenue of 922.5 billion yen.

Life plans to pay interim and year-end dividends of 35 yen per share each for the current fiscal year, which is higher than the 32.50 yen interim and 33 yen final dividends paid in the year-ago period.

Related Articles

Asia

Netwealth's FUA Net Flows in Fiscal Q4 Likely to See Seasonal Step-up, Jarden Says

Netwealth Group's (ASX:NWL) funds under administration (FUA) net flows are likely to see a seasonal step-up in the fiscal fourth quarter, which would see the fiscal 2026 outcome tracking slightly ahead of its guidance range, Jarden said in a Thursday note.It raised its earnings-per-share forecasts by 0.1% for fiscal 2026, 1.5% for fiscal 2027, and 1.6% for fiscal 2028.Jarden also flagged the risk of higher cost growth due to the enforceable undertaking, regulatory scrutiny, and recent treasury consultations.The investment firm retained its neutral recommendation on Netwealth Group and raised the price target to AU$25.70 from AU$25.35.Netwealth Group's shares gained 1% in recent Friday trade.

$ASX:NWL
Asia

CDL Hospitality REIT Issues Stapled Securities as Payment of Management Fee

CDL Hospitality REIT (SGX:J85) issued 5.5 million stapled securities to its manager, H-REIT Manager and HBT Trustee-Manager as payment of management fee for 2025, according to a Friday filing with the Singapore Exchange.Nearly 5 million stapled securities were issued to the H-REIT Manager at SG$0.8199 per security as 80% payment of its performance fee for 2025.Meanwhile, 535,179 securities were issued to HBT Trustee-Manager at SG$0.8199 per security as payment of 80% of performance fee for 2025.

$SGX:J85
Asia

Syntara's Myelofibrosis Drug Candidate Shows 'Significant' Commercial Potential, Euroz Hartleys Says

Syntara's (ASX:SNT) Amsulostat drug candidate has a "unique" position in the myelofibrosis landscape and "significant" commercial potential, Euroz Hartleys said in a Thursday note.Myelofibrosis is a blood cancer characterized by scar tissue formation or fibrosis in the bone marrow.Dr Adam Craig, Syntara strategic adviser and an industry leader in myelofibrosis, noted Amsulostat's mechanism targeting fibrosis, with the potential as a disease-modifying therapy, rather than just a symptomatic treatment.Craig said that Amsulostat's safety profile differs from current therapies and is unaware of any other drug taking a similar approach.Additionally, Craig said that Amsulostat's mechanism requires time for effect, as fibrosis evolves gradually. Patient responses observed at six months are complemented by a continuing improvement over time.Euroz Hartleys reaffirmed its speculative buy recommendation and AU$0.22 price target on Syntara.Syntara shares fell 1% in afternoon trade on Friday.

$ASX:SNT